Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.

Nieto García A, Garriga-Baraut T, Plaza Martín AM, Nieto Cid M, Torres Borrego J, Folqué Giménez MDM, Lozano Blasco J, Bosque García M, Moreno-Galarraga L, Tortajada-Girbés M, Rivas Juesas C, Penín Antón M, Caballero-Rabasco MA, Gaboli M, López Neyra A, Navarro Morón J, Freixa Benavente A, Valdesoiro Navarrete L, Ballester Asensio E, Sanz Santiago V, Romero García R, Gimeno Díaz de Atauri Á, Valenzuela Soria A, Sánchez Mateos M, Batlles Garrido J, Andrés Martín A, Campos Alonso E, Aragón Fernández C, Vázquez Rodríguez E, Martínez Pardo L, Del-Río Camacho G, Mazón Ramos Á

Open source

DOI: 10.1111/pai.13484
Published: 2021 Jul
Container: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/pai.13484,
  title = {Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.},
  author = {Nieto García A and Garriga-Baraut T and Plaza Martín AM and Nieto Cid M and Torres Borrego J and Folqué Giménez MDM and Lozano Blasco J and Bosque García M and Moreno-Galarraga L and Tortajada-Girbés M and Rivas Juesas C and Penín Antón M and Caballero-Rabasco MA and Gaboli M and López Neyra A and Navarro Morón J and Freixa Benavente A and Valdesoiro Navarrete L and Ballester Asensio E and Sanz Santiago V and Romero García R and Gimeno Díaz de Atauri Á and Valenzuela Soria A and Sánchez Mateos M and Batlles Garrido J and Andrés Martín A and Campos Alonso E and Aragón Fernández C and Vázquez Rodríguez E and Martínez Pardo L and Del-Río Camacho G and Mazón Ramos Á},
  year = {2021},
  journal = {Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology},
  doi = {10.1111/pai.13484},
  url = {https://doi.org/10.1111/pai.13484}
}

RIS

TY  - JOUR
TI  - Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
AU  - Nieto García A
AU  - Garriga-Baraut T
AU  - Plaza Martín AM
AU  - Nieto Cid M
AU  - Torres Borrego J
AU  - Folqué Giménez MDM
AU  - Lozano Blasco J
AU  - Bosque García M
AU  - Moreno-Galarraga L
AU  - Tortajada-Girbés M
AU  - Rivas Juesas C
AU  - Penín Antón M
AU  - Caballero-Rabasco MA
AU  - Gaboli M
AU  - López Neyra A
AU  - Navarro Morón J
AU  - Freixa Benavente A
AU  - Valdesoiro Navarrete L
AU  - Ballester Asensio E
AU  - Sanz Santiago V
AU  - Romero García R
AU  - Gimeno Díaz de Atauri Á
AU  - Valenzuela Soria A
AU  - Sánchez Mateos M
AU  - Batlles Garrido J
AU  - Andrés Martín A
AU  - Campos Alonso E
AU  - Aragón Fernández C
AU  - Vázquez Rodríguez E
AU  - Martínez Pardo L
AU  - Del-Río Camacho G
AU  - Mazón Ramos Á
PY  - 2021
JO  - Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
DO  - 10.1111/pai.13484
UR  - https://doi.org/10.1111/pai.13484
ER  -

APA

A, N. G., T, G., AM, P. M., M, N. C., J, T. B., MDM, F. G., J, L. B., M, B. G., L, M., M, T., C, R. J., M, P. A., MA, C., M, G., A, L. N., J, N. M., A, F. B., L, V. N., E, B. A., V, S. S., R, R. G., Á, G. D. D. A., A, V. S., M, S. M., J, B. G., A, A. M., E, C. A., C, A. F., E, V. R., L, M. P., G, D. C., & Á, M. R. (2021). Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13484

Source records

pubmed · retrieved 2026-11-10T11:37:00.342Z